XF-73 Data Announced
Destiny Pharma PLC (LSE:DEST) announced promising results for its lead drug, exeporfinium chloride, branded as XF-73, on Monday. The Brighton-based clinical-stage biotechnology company revealed data from a recent study indicating that XF-73 reduced MRSA infection in burn wound tissue by up to 99.99% compared to a placebo treatment. This study demonstrated the drug's effectiveness following a single topical application of 25, 50, or 100 micrograms of XF-73.
Significance of MRSA Reduction
MRSA, or methicillin-resistant Staphylococcus aureus, is a dangerous pathogen known for causing severe infections and potentially life-threatening sepsis with a high mortality rate. The results from the study are seen as a significant advancement in the development of XF-73, highlighting its potential to substantially reduce or eliminate MRSA from wound sites, thereby minimizing the risk of sepsis.
Chief Scientific Officer Bill Love commented on the study's results, stating that the data from the in vivo burn wound infection model provides compelling evidence of XF-73’s capability to significantly mitigate the risk of MRSA reaching the bloodstream and causing severe infections. This outcome is considered a key milestone for the continued development of XF-73 as a dermal product.